---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030944"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:32:58.390828+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Processa: PCS12852 Phase 2A improves gastric emptying (p<0.10); nine-month net loss $14.4M

## Summary
- PCS12852 Phase 2A: GEBT showed gastric emptying improvement for 0.5mg dose vs placebo (p<0.10); mild-to-moderate AEs, no serious events.
- Net loss for nine months ended Sep 30, 2022: $14.4M ($0.90/share) vs $8.2M ($0.54/share) YoY.
- Cash at Sep 30, 2022: $9.1M; expected to fund operations into Q3 2023.
- R&D expenses rose to $8.3M (up $3.5M) due to ongoing clinical trials; G&A $6.1M (up from $3.4M).
- Plans: Phase 2B trial for PCS12852 in 2023; NGC (PCS6422+capecitabine) Phase 2B planned after FDA meeting.

## SEC filing metadata
- accession: 0001493152-22-030944
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315222030944/0001493152-22-030944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315222030944/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030944
- JSON: https://secwatch.observer/filing/0001493152-22-030944.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030944.txt

## Key facts
- Earnings Releases
  Processa Pharmaceuticals, Inc. reported for the nine months ended September 30, 2022 results: net income $14.4 million, EPS $0.90 per share.
  - Period: for the nine months ended September 30, 2022
  - Net income: $14.4 million
  - EPS: $0.90 per share
  - Result: reported results
  source text: Our net loss for the nine months ended September 30, 2022, was $14.4 million or $0.90 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315222030944/0001493152-22-030944-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.